Therapeutic oligonucleotides (e.g., small interfering RNAs (siRNAs) and antisense) hold promise as transformative drugs for the treatment of genetically defined neurodegenerative disorders, including Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). siRNAs silence disease-causing genes by targeting their cognate mRNAs for degradation, thereby preventing the expression of toxic gene products. Their inherent sequence specificity and prolonged activity provide a powerful therapeutic platform, as long as the disease is genetically defined and delivery to the relevant target tissue is achievable. However, siRNAs do not cross the blood?brain barrier and local CNS delivery by injection often results in poor retention, distribution or toxicity. Thus, efficient and non-toxic delivery represents a major hurdle in the development of RNAi-based drugs to treat neurodegenerative disorders. The goal of this proposal is to develop and characterize novel chemical scaffolds that promote simple, efficient, and non-toxic delivery of oligonucleotides and potent silencing of therapeutic targets in the central nervous system. We describe a class of fully chemically stabilized hydrophobic siRNAs (hsiRNAs) that elicit durable and potent silencing throughout the brain following bolus cerebrospinal fluid (CSF) infusion. Modifications include oligonucleotides structure, ribose, backbone and the addition of lipophilic conjugates? e.g., neuroactive steroids, endocannabinoid-like lipids, gangliosides. Extensive structure-activity relationship studies reveal that the type of conjugate defines the distribution, retention, efficacy, duration of effect, and toxicity of hsiRNA-conjugates in the central nervous system. Completion of this proposal will (i) define and characterize two novel chemical scaffolds that support potent, specific, and long-lasting silencing of target genes in the central nervous system, and (ii) validate this new platform in animal models of HD and ALS, establishing a path towards novel treatments for two neurodegenerative diseases. This proposal establishes a platform that allows direct targeting of any gene expressed in any region of the central nervous system in a rodent. Successful completion of this work will enable studies of gene function in the central nervous system and pave the way towards development of novel oligonucleotide-based therapies for genetically defined neurodegenerative diseases.

Public Health Relevance

Therapeutic oligonucleotides are promising sequence-specific drugs for the treatment of genetically defined neurodegenerative disorders with unmet medical needs, including Huntington's disease and amyotrophic lateral sclerosis (ALS). Yet a lack of safe and effective delivery methods to the brain limits their utility. This proposal develops novel oligonucleotide chemistries that promote safe and widespread delivery to brain and spinal cord, with durable silencing activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS104022-01
Application #
9427313
Study Section
Drug Discovery for the Nervous System Study Section (DDNS)
Program Officer
Miller, Daniel L
Project Start
2017-09-25
Project End
2022-06-30
Budget Start
2017-09-25
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Genetics
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Biscans, Annabelle; Haraszti, Reka A; Echeverria, Dimas et al. (2018) Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles. Mol Ther 26:1520-1528
Didiot, Marie-C├ęcile; Ferguson, Chantal M; Ly, Socheata et al. (2018) Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell Rep 24:2553-2560.e5